Skip to main content
Fig. 2 | Journal of Hematology & Oncology

Fig. 2

From: Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study

Fig. 2

PFS (time from randomization to first documentation of PD or death) with ixazomib-Rd and placebo-Rd at data cut-off for primary and final analysis of PFS (median follow-up for PFS of 7.4 and 6.9 months, respectively). a Kaplan–Meier analysis of PFS by IRC assessment in the intent-to-treat population. b Forest plot of PFS in prespecified patient subgroups

Back to article page